|
Serum glial fibrillary acidic protein is a good marker for the diagnosis of Devic’s disease
|
|
| Author:
|
INAS K.SHARQUIE, GHEYATH AL GAWWAM
|
| Abstract:
|
Background: Devic’s disease involves the demyelination of the optic nerves and spinal cord. There is an important increase in the levels of Glial fibrillary acidic protein (GFAP) found in the cerebrospinal fluid (CSF) of patients with Devic’s disease, and it can also be detected in the blood of patients with traumatic brain injury, suggesting that serum sampling could provide a diagnostic measurement.
Objectives: This work sought to compare the serum concentration of GFAP in patients with Devic’s disease with that of healthy controls.
Patients and Methods: Individuals with Devic’s disease (n=24), as well as healthy controls (n= 24), were studied. Serum GFAP measures were assayed using enzyme-linked immunosorbent assay (ELISA).
Results: GFAP levels were significantly higher in subjects with Devic’s disease (mean concentration 3.86 ± 2.82 ng/ml) than in healthy controls (1.74 ± 0.96 ng/ml; p = 0.001). A cut-off value of 1.89 ng/ml was used for the estimation of serum GFAP ELISA test validity and showed good validity. The sensitivity and specificity were 79.2% and 72.0%, respectively, the positive predictive value (PPV) was 73.1%, the negative predictive value (NPV) was 78.3% and the ELISA test accuracy was 75.51%.
Conclusions: Measuring serum GFAP in Devic’s disease could be helpful in the diagnosis of the condition, and this test is easier to conduct as it is carried out on serum samples instead of CSF, as was previously the case.
|
| Keyword:
|
Devic’s disease; Neuromyelitis optica; NMO; Serum glial fibrillary acidic protein; GFAP.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.SP1.354
|
| Download:
|
Request For Article
|
|
|